Welcome to our dedicated page for Allarity news (Ticker: ALLR), a resource for investors and traders seeking the latest updates and insights on Allarity stock.
Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a Phase 2 clinical-stage biopharmaceutical company focused on personalized oncology through the development of stenoparib, a dual PARP1/2 and tankyrase 1/2 inhibitor, and its proprietary DRP® companion diagnostic platform. The Allarity news feed highlights how the company advances this program in advanced ovarian cancer and other hard-to-treat malignancies.
News updates commonly cover clinical trial milestones, such as enrollment progress and new Phase 2 data in platinum-resistant or platinum-ineligible ovarian cancer, including Kaplan–Meier analyses of overall survival and durability of response. Releases also report on regulatory developments, notably the FDA Fast Track designation granted to stenoparib for advanced ovarian cancer, and on scientific presentations at meetings like the AACR Special Conference on Ovarian Cancer and Biomarkers & Precision Medicine.
Investors and observers will find coverage of corporate and financial updates, including quarterly results, capital structure actions, and private placement transactions disclosed via Form 8-K. Additional news items describe the expansion of Allarity’s DRP® platform through licensing and laboratory services agreements with EU-based biotechnology partners, patent developments such as Australian acceptance for the stenoparib DRP®, and collaborations with institutions like the Indiana Biosciences Research Institute.
This page aggregates these announcements so readers can follow how Allarity is progressing stenoparib in ovarian cancer, preparing combination studies in recurrent small cell lung cancer, and broadening the use of its DRP® technology across oncology. For ongoing insight into trial data, regulatory interactions, intellectual property, and financing events related to ALLR, this curated news stream provides a centralized view.
Allarity Therapeutics (NASDAQ: ALLR) announced a VA-funded Phase 2 trial combining stenoparib with temozolomide in relapsed small cell lung cancer (SCLC), now open for enrollment at 11 VA sites across the US as of February 3, 2026. The study (NCT06681220) will assess safety and efficacy and uses a blood-based biomarker to select patients.
The trial tests stenoparib’s dual PARP/WNT inhibition and aims to improve tolerability versus prior PARP+temozolomide combinations while exploring activity against brain metastases.
Allarity Therapeutics (NASDAQ: ALLR) CEO letter dated December 31, 2025 reviews two years of strategic refocus and execution centered on stenoparib (2X-121), a dual PARP/WNT inhibitor for advanced ovarian cancer and other difficult cancers.
Key developments: FDA Fast Track designation for stenoparib; updated AACR data showing median overall survival not reached with median follow-up >22 months; two patients on therapy >30 months; a new Phase 2 protocol; a VA-funded recurrent small cell lung cancer trial; a DRP licensing and lab services agreement; simplified capital structure and restored Nasdaq compliance; selective share repurchases and a cash runway aligned with development goals.
Allarity Therapeutics (NASDAQ: ALLR) reported Q3 2025 results and operational updates on November 14, 2025. Key clinical progress includes FDA Fast Track designation for stenoparib in advanced ovarian cancer and Phase 2 data showing median overall survival now exceeding 25 months. The company signed a commercial license for selected DRP® breast cancer algorithms and maintains an IBRI research collaboration to study stenoparib’s dual PARP/WNT mechanism. Financially, Allarity ended Q3 with $16.9 million cash (down $0.9M QoQ) and a reported net loss of $2.8 million. The company expects a VA-funded SCLC combination trial to open by year-end 2025 and projects a financial runway through December 2026.
Allarity Therapeutics (NASDAQ: ALLR) has presented groundbreaking Phase 2 clinical data for stenoparib/2X-121 at the AACR Special Conference on Ovarian Cancer. The trial's Kaplan-Meier analyses revealed that median Overall Survival (mOS) has exceeded 25 months in platinum-resistant and refractory ovarian cancer patients.
Key highlights include two patients continuing therapy beyond 24 months, including one with wild-type BRCA gene. The drug shows clinical benefits regardless of BRCA status, distinguishing it from first-generation PARP inhibitors. Notably, stenoparib's mOS of >25 months significantly outperforms recent FDA-approved therapies' mOS of 16-16.5 months for platinum-resistant ovarian cancer (PROC) patients.
The drug demonstrates a favorable safety profile with reduced myelotoxicity compared to earlier PARP inhibitors, and its dual inhibition of PARP1/2 and WNT pathway shows promise for broader patient benefit.
Allarity Therapeutics (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company, announced that CEO Thomas Jensen will present at the Biomarkers & Precision Medicine 2025 conference in London. The presentation, scheduled for October 1, 2025, will focus on gene expression-based biomarkers for predicting treatment response to stenoparib, the company's dual PARP and WNT pathway inhibitor.
Jensen will also participate in an interview with Oxford Global's editorial team, discussing Allarity's research and DRP® companion diagnostic platform. The interview will be available on Oxford Global's online content portal. One-on-one meetings with the CEO will be available during the conference.
Allarity Therapeutics (NASDAQ: ALLR) has received FDA Fast Track designation for stenoparib, its investigational treatment for advanced ovarian cancer. This designation enables expedited development and review process, including more frequent FDA interactions and potential eligibility for accelerated approval.
The company is currently conducting a Phase 2 clinical trial evaluating stenoparib in advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cancer. The trial, which began enrollment in June 2025, builds on previous Phase 2 data that demonstrated durable clinical benefit, with some patients maintaining treatment for over 22 months.
Allarity Therapeutics (NASDAQ: ALLR) reported significant progress in Q2 2025, highlighted by the initiation of enrollment in their Phase 2 ovarian cancer trial for stenoparib, their dual PARP and WNT pathway inhibitor. The company secured an Australian patent for the Stenoparib DRP® companion diagnostic and established a new service contract with an EU biotech for their medical laboratory.
Financial highlights include a cash position of $17.8 million, implementation of a $2.6 million share repurchase program, and a $2 million reduction in accounts payable. Q2 2025 saw R&D expenses of $2.3 million (up from $1.06M in Q2 2024) and G&A expenses of $1.8 million (down from $2.3M). The company reported a net loss of $2.3 million for Q2 2025.
Notable appointments include Jesper Høiland to the Board of Directors and Jeffrey S. Ervin as CFO, strengthening the company's leadership team.
Allarity Therapeutics (NASDAQ: ALLR) has signed a new commercial agreement with an undisclosed EU-based biotech company for its DRP® platform technology. The agreement includes a non-exclusive global license for selected proprietary Allarity DRP® algorithms in breast cancer and laboratory services from Allarity's Medical Laboratory in Denmark.
The partnership involves advanced transcriptome analysis services to support precision oncology solutions in breast cancer, with committed purchases for laboratory services over the next year. The DRP® platform uses gene expression profiling to predict tumor responses to specific therapies. Allarity currently holds DRPs for over 100 drugs, including both investigational and approved medications.
Allarity Therapeutics (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company, has appointed Jeff Ervin as its new Chief Financial Officer. Ervin, who brings nearly 20 years of executive leadership experience, succeeds Alexander Epshinsky. He previously served as Co-CFO at NYSE-listed DayDayCook and CEO of NASDAQ-listed IMAC Holdings.
Ervin holds an MBA from Vanderbilt University and will initially join Allarity in a half-time capacity, with potential for full-time employment based on company needs. The company is focused on developing stenoparib, a dual PARP and WNT pathway inhibitor, as a personalized cancer treatment using its proprietary DRP® patient selection technology.
Allarity Therapeutics (NASDAQ: ALLR) has received a patent acceptance notice from IP Australia for its Stenoparib DRP® companion diagnostic. The acceptance covers 40 claims for the company's proprietary drug-specific Drug Response Predictor (DRP®) technology used in conjunction with stenoparib, their Phase 2 dual PARP and WNT pathway inhibitor for personalized cancer treatment.
The patent will be advertised in the Australian Official Journal of Patents on June 26, 2025, followed by a three-month opposition period. If unopposed, the patent should be granted within 20 working days. Allarity currently holds 18 granted patents for drug-specific DRPs, including eight in the United States, and has additional Stenoparib DRP® patent applications pending in the U.S., Canada, Japan, China, and India.
FAQ
What is the current stock price of Allarity (ALLR)?
What is the market cap of Allarity (ALLR)?
